Stem Cells Archives | Page 94 of 202

LifePlus Stem Cells Delivers its First Allogeneic Mesenchymal Stem Cells for the Treatment of Arthritis

February 1, 2021 By BioInformant Team Leave a Comment

LifePlus Stem Cells, a provider of innovative stem cell advancements, specialising in regenerative rehabilitation announces their first injection of its umbilical cord-derived allogeneic mesenchymal stem cells. Using a unique and highly regulated manufacturing process, LifePlus Stem Cells is able to provide patients and clinicians with the world’s purest allogeneic mesenchymal stem cells – achieving purity levels of well over 80%.

The Complete Guide To Virtual Stem Cell Conferences in 2021

January 22, 2021 By Cade Hildreth, Founder & President Leave a Comment

As the world has been rocked by the COVID-19 pandemic, most in-person conferences have been canceled or switched to online formats. This goes for stem cell conferences too. However, stem cell conferences are still happening in 2021, albeit mostly virtual.

Here is your complete guide to virtual stem cell conferences in 2021. Learn more below to decide which ones to attend. For ease of reference, they are organized by date. [Read more…]

Implant Therapeutics To Engineer iPSC-MSC Cells Containing panCELLa’s Technologies

January 13, 2021 By Cade Hildreth, Founder & President Leave a Comment

TORONTO, Jan. 8, 2021– panCELLa’s intent to develop therapeutic products in the mesenchymal stem cell (MSC) and pancreatic islet space has recently led to the creation of Implant Therapeutics.

Implant Therapeutics, under the guidance of Dr. Mahendra Rao, is engineering iPSC-MSC cells containing panCELLa’s FailSafe™ and induced Allogeneic Cell Tolerance (iACT Stealth Cell™) technologies. These iPSC MSC cells are hypo-immunogenic and are an ideal choice for bone, cartilage and tendon replacement strategies combining the advantages of allogeneic and autologous cells as well as allowing them to be used as ex-vivo gene therapy vehicles. [Read more…]

Evotec Achieves Milestone within iPSC-Based Neuroscience Partnership with BMS

January 9, 2021 By Cade Hildreth, Founder & President Leave a Comment

Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry.

HAMBURG, GERMANY / January 5, 2021 — Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced that the Company has received a US $6 million payment from Bristol Myers Squibb Company (NYSE: BMY) within the companies’ iPSC-based neuroscience partnership. The payment follows Bristol Myers Squibb’s decision to add another drug discovery project to the partnership’s portfolio. [Read more…]

Spinogenix Secures DOD Grant To Study Lead Compound in hiPSCs from Patients with ALS

January 8, 2021 By Cade Hildreth, Founder & President Leave a Comment

Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)

SAN DIEGO, Calif., Jan. 05, 2021 — Spinogenix, Inc. a preclinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced that it will be collaborating with Dr. Rita Sattler at the Barrow Neurological Institute and Dr. Justin Ichida at the USC Keck School of Medicine on a grant awarded from the U.S. Department of Defense’s (“DOD”) Congressionally Directed Medical Research Programs (“CDMRP”) to evaluate its lead development candidate in ALS. [Read more…]